Health

No Image

Department Of Veterans Affairs To Pay For Robotic Legs

ReWalk Robotics service engineer Tom Coulter (right) looks on as paralyzed Army veteran Gene Laureano walks using a ReWalk device on Wednesday in the Bronx, N.Y.

ReWalk Robotics service engineer Tom Coulter (right) looks on as paralyzed Army veteran Gene Laureano walks using a ReWalk device on Wednesday in the Bronx, N.Y. Mel Evans/AP hide caption

toggle caption Mel Evans/AP

Eligible veterans with spinal cord injuries may soon be able to walk again.

The Department of Veterans Affairs will now pay for robotic leg devices for eligible paralyzed veterans, VA officials tell The Associated Press.

Dr. Ann Spungen, who led VA research on the device, told AP that the announcement represents a major shift in policy:

“The research support and effort to provide eligible veterans with paralysis an exoskeleton for home use is a historic move on the part of the VA because it represents a paradigm shift in the approach to rehabilitation for persons with paralysis.”

Previously, the $77,000 cost of the device was prohibitively expensive for many injured veterans.

This video from ReWalk, the company that developed and manufactured the robotic legs, shows how its “wearable robotic exoskeleton” works:

[embedded content]

This video from ReWalk, the company producing the robotic legs, shows how they work.

YouTube

The system allows people to stand upright and walk, and uses “wearable brace support, a computer-based control system and motion sensors,” ReWalk says in a statement. The FDA approved the system in 2014 for home use.

ReWalk says that the VA’s decision means that veterans with spinal cord injuries can seek referral and evaluation at training centers around the country. Once an individual receives training, they’ll be considered for a personal unit to use outside the center.

“The policy outlines a sound process to educate, train and importantly, to provide individual veterans with a ReWalk Personal device so that they may walk at home and in the community,” says ReWalk CEO Larry Jasinski in the press release from the company. “We expect this landmark national policy will substantially improve the health and quality of life of many veterans in the years ahead.”

But for most paralyzed veterans, there are more than just financial obstacles. NPR’s Amy Held reported for our Newscast unit that the ReWalk “only works for certain paraplegics who meet height and weight requirements.” That’s only a fraction of the tens of thousands of paralyzed vets, she says.

A ReWalk representative tells Held that the company has so far determined that 45 paralyzed veterans meet the criteria for the device and have begun the process of seeking enrollment in the program.

AP spoke with Gene Laureano, a 53-year-old veteran who was part of a study on the robotic legs. Now, he’s eagerly waiting for a response on his application for the system—and describes how much it meant to him during the study.

” ‘The tears came down,’ said Laureano, who was left paralyzed five years ago after falling off a ladder. ‘I hadn’t spoken to somebody standing up in so long.’

” ‘I just kept remembering the doctor told me it was impossible for me to walk, and then I crossed that threshold from the impossible to the possible.’ “

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

Obamacare Enrollment Extended To Accommodate Last-Minute Demand

The deadline to buy health insurance under Obamacare has been extended for two days after high demand clogged the federal government’s exchange.

The Department of Health and Human Services announced Tuesday night, just hours before the original deadline of midnight Dec. 15, that consumers would have 48 hours more to buy a health plan.

Wait times to log in to HealthCare.gov or to get help on the telephone were so long earlier this week that officials said anyone who left a message or email address would be contacted after Tuesday’s deadline and would still be able to get insurance that goes into effect on Jan. 1.

By Tuesday, more than a million people had left telephone messages, so Department of Health and Human Services decided to give people more time.

Andy Slavitt, acting administrator of the Centers for Medicare and Medicaid Services, which oversees HealthCare.gov, said on Twitter that 185,000 people were simultaneously shopping for insurance late Monday.

People may be motivated by higher penalties that kick in next year for not having insurance.

In 2016, an individual who doesn’t buy insurance will owe at least $695 when filing taxes for that year. The fines increase based on income, and can go up to $2,085 for an individual.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

Hepatitis Drug Among The Most Costly For Medicaid

Sovaldi can cure hepatitis C, but the medicine carries a list price of $1,000 a pill. The typical 12-week course of treatment would cost $84,000.

Sovaldi can cure hepatitis C, but the medicine carries a list price of $1,000 a pill. The typical 12-week course of treatment would cost $84,000. Bob Ecker/MCT/Landov hide caption

toggle caption Bob Ecker/MCT/Landov

A drug that can cure hepatitis C was one of the top pharmaceutical costs in most states’ Medicaid budgets in 2014.

All told, 33 states spent more than $1 billion to treat the disease with Gilead Sciences’ Sovaldi, according to data released Tuesday by Sens. Charles Grassley, R-Iowa, and Ron Wyden, D-Ore. Still, the money spent was enough to treat only 2.4 percent of Medicaid patients infected with the virus.

New York spent the most by far. That state’s Medicaid program shelled out more than $360 million for Sovaldi to treat about 4,000 of its nearly 60,000 Medicaid recipients who have hepatitis C.

Pennsylvania was next, spending $98 million last year to treat 1,059 Medicaid recipients with hepatitis C. Another 30,000 Pennsylvanians are infected, the data show.

In a letter to the senators, Pennsylvania’s secretary of human services said the state was suffering from “sticker shock” and said the price affected the state’s decision about whether to treat patients with the hepatitis drug.

“Treatment guidelines recommended prioritizing treatment for the ‘sickest’ patients due to potential costs and access issues,” said Secretary Theodore Dallas in the letter.

Many states also spent smaller amounts on Harvoni, Gilead’s other hepatitis drug, which was approved near the end of 2014.

When Sovaldi was approved in December 2013, it was the first drug that could effectively cure hepatitis C, a virus that attacks the liver and can lead to cirrhosis, cancer and the need for a transplant.

The Centers for Disease Control and Prevention estimated that 2.7 million people in the U.S. had chronic hepatitis C infections in 2013.

Sovaldi became the center of controversy when Gilead set the price at $1,000 a pill, or $84,000 for a course of treatment. Harvoni is even pricier.

In early December, Grassley and Wyden released a report from an 18-month investigation showing that Gilead was fully aware its pricing strategy would be controversial, but decided to stick with it to maximize revenue.

That report said sales of the two drugs since they were launched reached $20.6 billion as of September.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

You Can Buy Insulin Without A Prescription, But Should You?

Carmen Smith now gets the insulin she needs via her doctor's prescription. When she lacked health insurance, buying a version of the medicine over the counter was cheaper, she says. But it was hard to get the dose right.
4:48

Download

Carmen Smith now gets the insulin she needs via her doctor’s prescription. When she lacked health insurance, buying a version of the medicine over the counter was cheaper, she says. But it was hard to get the dose right. Lynn Ischay for NPR hide caption

toggle caption Lynn Ischay for NPR

As anyone with diabetes can tell you, managing the disease with insulin usually means regular checkups at the doctor’s office to fine-tune the dosage, monitor blood-sugar levels and check for complications.

But here’s a little known fact: Some forms of insulin can be bought without a prescription.

Carmen Smith did that for six years when she didn’t have health insurance and didn’t have a primary care doctor. She bought her insulin without a prescription at Wal-Mart.

“It’s not like we go in our trench coat and a top hat, saying, ‘Uh I need the insulin,’ ” says Smith, who lives in Cleveland. “The clerks usually don’t know it’s a big secret. They’ll just go, ‘Do we sell over-the-counter insulin?’ “

Once the pharmacist says yes, the clerk just goes to get it, Smith says. “And you purchase it and go about your business.”

But it’s still a pretty uncommon purchase.

Smith keeps the tools for controlling her diabetes in this kit, which contains metformin, syringes, fast-acting insulin for daytime use and slow-release for overnight.

Smith keeps the tools for controlling her diabetes in this kit, which contains metformin, syringes, fast-acting insulin for daytime use and slow-release for overnight. Lynn Ischay for NPR hide caption

toggle caption Lynn Ischay for NPR

Smith didn’t learn from a doctor that she could buy insulin that way. In fact, many doctors don’t know it’s possible. When she no longer had insurance to help pay for doctors’ appointments or medicine, Smith happened to ask at Wal-Mart if she could get vials of the medicine without a prescription. To figure out the dose, she just used the same amount a doctor had given her years before.

It was a way to survive, she says, but no way to live. It was horrible when she didn’t get the size of the dose or the timing quite right.

“It’s a quick high and then, it’s a down,” Smith says. “The down part is, you feel icky. You feel lifeless. You feel pain. And the cramps are so intense — till you can’t walk, you can’t sit, you can’t stand.”

Smith says her guesswork put her in the emergency room a handful of times over the years.

The availability of insulin over the counter presents a real conundrum. As Smith’s experience shows, without training or guidance from a health care provider, it can be dangerous for a patient to guess at the best dosage and timing from version to version of insulin. On the other hand, being able to afford and easily buy some when she needed it may have saved her life.

There are two types of human insulin available over the counter; one made by Eli Lilly and the other by Novo Nordisk. These versions of the medicine are older, and take longer to metabolize than some of the newer, prescription versions; they were created in the early 1980s, and the prices range from more than $200 a vial to as little as $25, depending on where you buy them.

Dr. Jorge Calles, an endocrinologist at MetroHealth, Cleveland’s public hospital, is alarmed to think that some people are self-medicating with any sort of insulin.

“It’s a very serious situation if they are selling it over the counter — without any control with a prescription, specifically,” Calles says.

According to the medical consulting firm IMS Health, about 15 percent of people who buy insulin in the growing U.S. diabetes market purchase it over the counter without a prescription.

The U.S. Food and Drug Administration declined multiple requests by NPR for an interview on this topic. But, in an email, an FDA representative said that the versions of insulin now available over the counter were approved for sale that way because they are based on a less concentrated, older formulation, “that did not require a licensed medical practitioner’s supervision for safe use.”

The broader availability of this form of insulin allows patients with diabetes to obtain it “quickly in urgent situations, without delays,” the FDA says, and is intended to increase patient safety.

Still, some people with diabetes, as well as some doctors, doubt that the benefits of that greater availability outweigh the risks, especially for patients who switch from one type of insulin to another without telling their doctor.

“This is not something that should be done without the help of a professional,” says David Kliff, who has Type 1 diabetes and writes the Diabetic Investors blog. Kliff has followed and written about the expanding business of diabetes for years.

FDA officials are “basically sticking their heads in the sand” on this issue, Kliff says, and making a lot of assumptions.

“They look at insulin as a drug,” he says, “and say, ‘There’s this enormous body of evidence that shows that the drug is safe.’ But, you know, there’s a little asterisk at the end there. What the little asterisk basically says is: ‘You know, that’s assuming that the patient is trained on it.’ “

When asked about safety concerns, the FDA told NPR that the agency welcomes more research into the safety of over-the-counter insulin.

One state does require prescriptions for all insulin. Dr. Kevin Burke, a health officer for Clark County, Ind., led the effort to require prescriptions in his state.

“I didn’t realize that insulin was over the counter in Indiana until two of my patients, who were in good control, suddenly had increased glucoses,” Burke says. He asked them if they had changed their diet, lost weight, altered their workout routines. They had not.

“They both admitted that they had decided to switch to over-the-counter insulin,” Burke says, “which was different from what I had prescribed.”

Over time, taking the wrong dosages destroys your body, Burke says. Poorly managed diabetes is the cause of a host of complications, such as high blood pressure, kidney disease, nerve damage, loss of eyesight and stroke.

Burke says he took his concerns to the American Medical Association. But the national doctor’s association told him there are no data showing that the drug’s over-the counter availability is a public health hazard. In fact, the AMA’s board noted, getting insulin without a doctor’s prescription may be an important way for some insulin-dependent patients to get access to the medicine they need.

Dr. Todd Hobbs is chief medical officer of Novo Nordisk in North America, which makes Novolin, one of the two versions of insulin sold over the counter. His company partners with Wal-Mart to sell its version under the brand name ReliOn. (Wal-Mart declined to be interviewed for this story.)

Hobbs says Novo Nordisk’s version of insulin is for people who don’t have insurance, or who have to pay a lot for their other prescriptions — “people who just, for whatever reason, have fallen through the cracks and either don’t have insurance coverage at the time or are without coverage.”

With ever-rising copays and premiums, he says, many patients are turning to nonprescription insulin because it’s cheaper and all they can afford.

“But we hope to try to help them to not have to do that,” Hobbs says.

“We clearly think the newer versions are more close to what the body would do on its own,” he says. The prescription versions are better and safer, he agrees, because they make it easier for patients to avoid wild fluctuations in blood sugar.

Carmen Smith doesn’t blame the insulin she was taking for her emergency room visits.

“Insulin is not the problem,” she says. “It is getting the insulin that is the problem. Once I got connected with my physician, life as a diabetic got a lot less complicated for me.”

Smith is now on Medicaid. She has a doctor — and a prescription for one of the newer generations of insulin.

This story is part of NPR’s reporting partnership with WCPN ideastream and Kaiser Health News.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

California Expands Substance Abuse Treatment For Low-Income Residents

After years fighting a heroin addiction, Danny Montgomery, 33, is receiving inpatient treatment that is being paid for by Los Angeles County.

After years fighting a heroin addiction, Danny Montgomery, 33, is receiving inpatient treatment that is being paid for by Los Angeles County. Anna Gorman/KHN hide caption

toggle caption Anna Gorman/KHN

California is overhauling its substance abuse treatment system for low-income people, embarking on a massive experiment to create a smoother path for addicts from detox through recovery.

The state is the first to receive federal permission to revamp drug and alcohol treatment for beneficiaries of Medicaid, known as Medi-Cal in California. Through what’s known as a drug waiver, state officials will have new spending flexibility as they try to help people get sober and reduce social and financial costs of people with substance abuse disorders.

Under the waiver, the state plans to expand treatment services, including inpatient care, case management, recovery services and added medication. Beginning next year, drug treatment centers will be able to get reimbursed for providing this much wider range of options to people on Medi-Cal.

Only a small fraction of low-income Californians with substance abuse disorders receive treatment, largely because of restrictions on what Medicaid will pay for.

“This was a long time coming,” said Keith Lewis, executive director of Horizon Services, which provides treatment in San Mateo, Santa Clara and Alameda counties. “It’s a win/win for people with substance use issues and their families … and for the people providing those services.”

The changes, which will be phased in starting next year, stem in part from the Affordable Care Act, which required that substance abuse treatment be covered for people newly insured through Medicaid or insurance exchanges. The health law allowed states to expand Medicaid to cover millions more people.

Drug rehabilitation providers say the changes will give addicts a better chance at getting — and staying — clean. But they fear the state won’t raise the traditionally low Medi-Cal reimbursement rates for treatment, making it harder to provide services and produce the outcomes California is hoping for.

Lewis, of Horizon Services, said that under the waiver he expects drug treatment services to be higher quality and the workforce better trained. But he said that “Medi-Cal rates, which have always been too low, have to go up.”

California’s Medi-Cal drug treatment program currently costs about $180 million annually, paid through a combination of state and federal funds. There aren’t any estimates for costs under the new approach. But the idea is that the changes will help health care expenses overall by enabling more people to get sober and healthier so they stop rotating through treatment centers, jails and hospitals.

Nearly 14 percent of Medicaid recipients are believed to have a substance abuse disorder, according to the National Survey on Drug Use and Health.

The five-year pilot project in California was approved by the federal Centers for Medicare & Medicaid Services in August. Under the waiver, counties will approve treatment for Medi-Cal patients based on medical necessity and criteria established by the American Society of Addiction Medicine.

The Tarzana Treatment Centers in Los Angeles County provide outpatient and inpatient care for substance use disorders.

The Tarzana Treatment Centers in Los Angeles County provide outpatient and inpatient care for substance use disorders. Anna Gorman/KHN hide caption

toggle caption Anna Gorman/KHN

Current federal rules limit drug treatment centers’ ability to get reimbursed under Medicaid for residential care. Clinics with more than 16 beds essentially cannot get paid, except for treating pregnant and postpartum women. That restriction will be dropped for California under the waiver.

As a result, Medi-Cal beneficiaries will be able to access up to two 90-day residential stays each year, with the possibility of one 30-day extension if providers determine that it is medically necessary. Certain populations, including those in the criminal justice system, can get approval for longer stays.

The waiver is also designed to provide better coordination between physical, mental health and substance abuse services,” according to John Connolly, deputy director of substance abuse prevention and control for the Los Angeles County Department of Public Health. That along with more access could result in fewer emergency room visits and hospitalizations, he said.

That’s potentially good news for people like Caitlin Knoles, a resident of Orange County who says she gets turned down for treatment of her methamphetamine addiction every time she tells residential centers she’s on Medi-Cal. She has ended up in the hospital more than once because of her addiction.

“It’s hard,” Knoles said. “I can’t get help.”

The only way she can reliably get clean now is in jail, she says.

“It’d be nice to have a job and have my family back and just be normal,” said Knoles, 24, as she sat outside a liquor store in Laguna Hills.

For the first time, substance abuse disorders will be treated like a disease rather than a short-term illness, said Marlies Perez, chief of the substance use disorder compliance division for the state Department of Health Care Services. “Even though we know it’s a chronic condition, we have treated it acutely,” she said.

Much depends, however, on reimbursement rates, which are still being negotiated. Clinic officials say they need higher rates to expand services and handle the anticipated influx of clients, many of whom will be seeking rehab for the first time.

“There is a cost to raising the bar on treatment,” said Albert Senella, president of the California Association of Alcohol and Drug Program Executives. “If the rates aren’t adequate … we are not going to be able to effectively meet the [new requirements] and the needs of the population.”

Senella, who is also CEO of Tarzana Treatment Centers in Tarzana, Calif., said many clinics across the state don’t have money to prepare for the overhaul, which will require improving technology and adding and training staff. For now, no plans are in place to provide counties or clinics with startup funds.

Eli Veitzer, interim CEO of Prototypes, which provides treatment services in Los Angeles, Orange and Ventura counties, said the waiver provides an “incredible opportunity” to transform care.

But in addition to fears about rates, Veitzer said he is also worried that 90 days of residential treatment won’t be enough for many people. Someone may be able to stem their addiction in three months but will still need more time in a treatment facility to prepare for life outside.

“If their ability to function independently in the community is not addressed, they are likely to relapse,” he said.

Danny Montgomery, a 33-year-old patient at Tarzana Treatment Centers, said he needed more than a few months to get clean after nearly a decade on heroin. The addiction, which he estimated cost him up to $100 a day, caused him to lose his job and nearly lose his family.

“The whole thing is a process,” said Montgomery, who lives in the San Fernando Valley. “You get the substance removed from your body, but you have to retrain your mind.” Montgomery said he tried to get a bed in a residential treatment center but couldn’t find one that would take Medi-Cal.

He tried to get clean on his own but it never lasted. Months after beginning his search, Montgomery was finally able to get a spot at Tarzana. He said Los Angeles County is paying for his stay, which began in May.

As worried as they are about reimbursements, clinic operators said a big advantage of the new approach is that it could help stabilize their funding. Providers now depend largely on counties to pay for residential treatment for low-income residents.

“You always suffered the vagaries of the budget cycle,” said Vitka Eisen, CEO of HealthRIGHT 360, which provides drug treatment in the Bay Area.

The waiver also means increased oversight of treatment centers.

Last year, a state audit found widespread fraud and questionable billing among Medi-Cal drug treatment providers. The audit followed reports by the Center for Investigative Reporting that clinics were billing for fake clients.

The new system will include more levels of accountability, Perez says, including more stringent requirements for clinics and more local control over contracting.

Knoles, who is addicted to methamphetamine, said she hopes that more people like her will be able to get treatment.

“I’ve had a lot of friends die from addiction,” she said. “Imagine if they’d gotten the help they wanted and needed. Things would have been different.”

Anna Gorman is a reporter with Kaiser Health News, a nonprofit news organization covering health care policy and politics. A version of this story appeared on KQED’s State of Health blog.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

Limits Urged On The Use Of Codeine To Stop Kids' Coughs And Pain

Cessation of breathing is a rare, but serious risk for some children who take cough syrup or painkillers that contain codeine, research shows. Advisers to the FDA say no one under 18 should take the drug.
1:32

Download

Cessation of breathing is a rare, but serious risk for some children who take cough syrup or painkillers that contain codeine, research shows. Advisers to the FDA say no one under 18 should take the drug. iStockphoto hide caption

toggle caption iStockphoto

Medical advisers to the Food and Drug Administration say that prescription drugs containing codeine should not be used to treat children or the majority of teens suffering from pain or a cough.

In their meeting Thursday, the advisers also voted overwhelmingly against the over-the-counter sales of codeine-containing cough syrup for children. Selling such products without a prescription is currently permitted in 28 states and the District of Columbia.

The votes to restrict codeine’s use among children came at the end of a daylong joint meeting of the FDA’s Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee, in Silver Spring, Md. The FDA does not have to follow the recommendations of its advisory committees, but it usually does.

“My concern, were I to be prescribing codeine in children, would be that I would, frankly, kill them,” said pharmacist Maria Pruchnicki, of the Ohio State University College of Pharmacy.

Several committee members noted that there are questions about whether codeine is even effective for alleviating children’s coughs, and whether there are potentially safer alternatives for alleviating pain.

Although the administration of products containing codeine to children has dropped sharply over the past decade, doctors often still prescribe medicines that contain the drug, and parents can buy cough remedies that include codeine without a prescription in many parts of the country.

Codeine combined with other painkillers, such as acetaminophen, is also commonly used to alleviate kids’ pain in a variety of situations, such as when they’re recovering from surgery.

But the FDA has been increasingly concerned because codeine has been found to trigger life-threatening breathing problems in some children.

Such complications seem to be fairly rare, but they do occur — especially among children whose bodies are genetically predisposed to quickly convert codeine into morphine.

The FDA convened the panel of outside experts to advise the agency on what action to take, if any, in restricting the drug’s use.

During the daylong hearing, FDA scientists made presentations on dozens of frightening cases in which children stopped breathing after getting codeine, including at least two dozen deaths in the last decade.

Also, representatives from the American Academy of Pediatrics , and the National Center for Health Research, an advocacy group in Washington, D.C., urged the FDA to follow the lead of regulators in Europe, Australia and Canada, who have sharply restricted the drug’s use.

“The use of codeine or any other opioid cannot be recommended for the treatment of cough in children,” said Dr. Constance Houck, an anesthesiologist at Boston Children’s Hospital, speaking on behalf of the academy. The pediatricians’ group recommended against using codeine for pain, and urged the FDA to bar the sale of products containing the drug without a prescription.

The Consumer Healthcare Products Association, which represents companies that make over-the-counter codeine products, urged the FDA to base any decision “on sound scientific evidence.”

The manufacturers’ association reminded the agency that codeine had been deemed earlier “to be generally recognized as safe and effective,” and any decision to remove codeine from over-the-counter sales should go “thorough a multi-step process.”

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

Accused Planned Parenthood Shooter Shouts 'I'm Guilty' In Court

3:32

Download

Robert Dear, the man accused in the mass shooting at a Planned Parenthood office at Colorado Springs, blurted he was guilty Wednesday in court, one of several outbursts during his arraignment.

Transcript

AUDIE CORNISH, HOST:

In Colorado Springs, the man accused in the mass shooting at a Planned Parenthood office there was arraigned. Robert Dear faces multiple charges, including first-degree murder. Dear’s legs and arms were cuffed, and he frequently interrupted the court proceedings, yelling several times. Colorado public radio’s Ben Markus was in the courtroom, and he joins us now. And Ben Markus, to start, this was the first time that Dear appeared in person in court since his arrest. Can you describe the proceedings? What happened?

BEN MARKUS, BYLINE: Sure. While his lawyers were discussing pretty routine matters related to future media coverage, Dear suddenly shouted that he was guilty and that he’s, quote, “a warrior for the babies.” Dear had more than a dozen outbursts in the hour-long hearing, including, quote, “kill the babies; that’s what Planned Parenthood does,” unquote. He ranted that he saw atrocities in the clinic and lots of blood. He accused his public defenders, at one point, of conspiring with Planned Parenthood against him. He said he wouldn’t submit to a mental health evaluation, fearing that his attorneys would try to drug him up.

CORNISH: What was the reaction in court to all of this?

MARKUS: It sent a jolt through the courtroom at first, but the judge pretty much let him rant throughout the hearing. Dear’s public defenders seemed to be shaken by the outbursts, especially when he accused them of trying to drug him up. When Dear wouldn’t let the judge talk near the end of the hearing, a deputy sheriff touched him on the shoulder, whispered something into his ear. And after that, he was pretty quiet.

CORNISH: Remind us what’s going on with this investigation, what’s known about this shooting which took place the day after Thanksgiving.

MARKUS: Right. The attack happened at a Planned Parenthood clinic which offers abortion services among many other things. Many of the details of the shooting are still not known. What is known is prosecutors allege that Robert Dear killed three people, one police officer and two civilians that day. He wounded at least nine more in what was a tense five-hour standoff with police until he surrendered.

CORNISH: So happens next for Robert Dear?

MARKUS: He’ll be back in court in two weeks for a status hearing. His public defender told the judge, obviously, in light of Dear’s repeated outbursts today, that there are mental health issues and issues of competency to work out before a preliminary hearing or any other hearings can be held in this case. After the preliminary hearing, if that happens, Dear can enter a plea in the case. And then at that point, the district attorney will have to decide if they seek the death penalty or not.

CORNISH: This is a closely watched case in Colorado Springs. What was the scene in and around the courtroom? I don’t know what kind of bystanders were there and what they were saying.

MARKUS: Victims and their family were here. There were many people milling about out front. You know, it is – as soon as somebody says the Planned Parenthood shooting, people know exactly what it is. It is – has been front-page news, headline news. It’s been in, you know, most newscasts every single day. So people know right away when you say Planned Parenthood down here what they’re talking about.

CORNISH: And you mentioned victims’ families being in the courtroom. What was their reaction to Robert Dear yelling out?

MARKUS: They seemed shocked, just as shocked as the public defenders were. Some gasped, clearly did not expect him to outburst like that in the middle of court proceedings.

CORNISH: That’s Colorado Public Radio’s Ben Markus. He’s following the mass shooting case at a Planned Parenthood office in Colorado Springs where there was a court appearance of the defendant in that case today, Robert Dear. Ben, thanks so much for talking with us.

MARKUS: Thanks for having me.

Copyright © 2015 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR’s programming is the audio.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

Drug Cocktails Fuel Massachusetts' Overdose Crisis

A "speedball" mix of heroin and cocaine has caused overdose deaths for decades. Today, high-risk blends may alternatively include heroin or opioid pain pills plus Klonopin, Clonidine, or Fentanyl.
4:10

Download

A “speedball” mix of heroin and cocaine has caused overdose deaths for decades. Today, high-risk blends may alternatively include heroin or opioid pain pills plus Klonopin, Clonidine, or Fentanyl. Marianne Williams Photography/Flickr RM/Getty Images hide caption

toggle caption Marianne Williams Photography/Flickr RM/Getty Images

In a brick plaza next to the Chelsea, Massachusetts city hall, Anthony, a bald but still-youthful man in grey sweats, tells me he spent the previous night in the hospital for what he says was his twelfth overdose.

Anthony and other users of illegal drugs agreed to speak to NPR for this story on the condition that we use only their first names. He blames his overdose on what his dealer told him was a particularly strong bag of heroin laced with the anesthesia drug fentanyl — or something like it.

“He told me how strong it was,” Anthony says, “but everyone says that to sell their dope. The potency now is so inconsistent, you don’t know. So you’ll eat a bunch of Klonopins and do a shot of heroin, and then you’re dead.”

Among 501 overdose deaths assessed by the Office of the Chief Medical Examiner in Massachusetts in the first six months of 2014, and analyzed by the Harvard T.H. Chan School of Public Health, the vast majority were caused by heroin or a prescription opioid taken in combination with some other drug or alcohol. Fentanyl, a synthetic opiate that’s many times more powerful than heroin, was present in about 37 percent of the deaths, the researchers found. Klonopin, Xanax and other anti-anxiety benzodiazepines showed up in 13 percent of the Massachusetts overdose deaths.

Anthony says many users figure the risk from taking one of these multi-drug “cocktails” is worth the extra $2, or so, per additional pill.

“It intensifies the heroin high, and keeps you high longer,” he says.

On the street, there’s a hot market for lots of different prescription medications.

Using heroin in combination with other drugs is certainly not new. The speedball mix of heroin and cocaine that is present in some of the overdose deaths has been a popular high-risk choice for decades. Patients on methadone describe another popular cocktail taken after their daily dose of methadone treatment: gabapentin (anti-seizure medication), Klonopin, clonidine (treats high blood pressure and attention deficit hyperactivity disorder) and an over-the-counter allergy medicine.

“Little do you know that they all take a toll on your heart and on your breathing,” says Nicole, another drug user, who says she’s on methadone treatment for her heroin addiction.

Some heroin users pill-shop, she says, knowing which symptoms to mention so their doctor will prescribe something for anxiety or depression. And patients who have a legitimate need for these medications, who take them as prescribed, sometimes also experience an overdose.

“You trust your doctor,” Nicole says. “You think, ‘Oh, my doctor’s giving this to me, so it’s fine. Nothing’s going to happen to me — like I’m prescribed to take it.’ “

But many other people take the mixture with the aim of getting high, she says. “I think that the cocktail’s a more common thing than heroin is now. Or, most people that take heroin take the cocktail as well.”

Doctors who treat patients in recovery face difficult choices. Patients often describe increased anxiety, depression or trouble sleeping. But methadone and benzodiazepines can both suppress breathing; for someone who is on methadone, using benzodiazepines to calm anxiety can trigger a serious adverse reaction.

Even physicians who specialize in addiction medicine have trouble figuring out what to prescribe for anxiety or depression when a heroin patient is the doctor’s office begging for help, says Dr. Kavita Babu, a toxicologist at the University of Massachusetts Medical School.

“Not only is it difficult to put our knowledge of pharmacology into play,” she says, “but sometimes, [when] managing patient expectations about how their pain or anxiety should be treated, our clinical knowledge falls apart at the bedside.”

Now, with the revelation that most overdose deaths in Massachusetts stem from a toxic mix of heroin or prescription pain medicine with alcohol, cocaine or fentanyl, leading physicians and officials are urging all doctors to be more careful in their prescribing habits. They’ve pledged to update a state database where doctors are supposed to input the drugs they prescribe for each of their patients.

Mixing these drugs in toxic ways is “a big problem,” says Dr. Jim O’Connell, president of the Boston Health Care for the Homeless Program. “We’ve just been scratching the surface on it.” O’Connell says he asks patients which pills are big sellers on the streets and tries to avoid prescribing them.

“We, as doctors, don’t really have a good sense of what we should be prescribing, what we shouldn’t,” O’Connell says. “It’s really the combination of other drugs that is going to be the battle down the line.”

Many addiction specialists say society also needs to pay more attention to the emotional pain at the root of addiction.

In Chelsea, Anthony shows me the park bench where’s he’s overdosed a dozen times.

“There’s times when I really do want to die,” he says.

I ask him why, and Anthony’s face crumples in silent sobs.

“The more I do, the more guilt I feel and the more I want to kill myself,” he says. He struggles with “the guilt and the pain and shame” for the repeated relapses.

Anthony clutches his hospital discharge notes in one hand. The notes say he should call his doctor and psychiatrist, and schedule follow-up appointments. Anthony doesn’t have a phone. When I offer him mine to make the call, he gets the answering service. He doesn’t leave a number.

This story is part of NPR’s reporting partnership with WBUR and Kaiser Health News.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

Marijuana Extract May Help Some Children With Epilepsy, Study Finds

A strain of high-cannabidiol marijuana is used to create extracts used in experimental epilepsy treatments.

A strain of high-cannabidiol marijuana is used to create extracts used in experimental epilepsy treatments. GW Pharmaceuticals hide caption

toggle caption GW Pharmaceuticals

Parents of children with severe epilepsy have reported incredible recoveries when their children were given cannabidiol, a derivative of marijuana. The drug, a non-psychoactive compound that occurs naturally in cannabis, has been marketed with epithets like Charlotte’s Web and Haleigh’s Hope.

But those parents were taking a risk; there has been no clinical data on cannabidiol’s safety of efficacy as an anti-epileptic. This week, doctors are presenting the first studies trying to figure out if cannabidiol actually works. They say the studies’ results are promising, but with a grain of salt.

The largest study being presented at the American Epilepsy Society meeting in Philadelphia this week was started in 2014 with 313 children from 16 different epilepsy centers around the country. Over the course of the three-month trial, 16 percent of the participants withdrew because the cannabidiol was either ineffective or had adverse side-effects, says Dr. Orrin Devinsky, a neurologist at the New York University Langone Medical Center and lead author on the study.

But for the 261 patients that continued taking cannabidiol, the number of convulsive seizures, called grand mal or tonic-clonic seizures, went down by about half on average. Devinsky says that some children continued to experience benefits on cannabidiol after the trial ended. “In the subsequent periods, which are very encouraging, 9 percent of all patients and 13 percent of those with Dravet Syndrome epilepsy were seizure-free. Many have never been seizure-free before,” he says. It’s one of several [at least four. checking] papers on cannabidiol being presented this week at the American Epilepsy Society meeting in Philadelphia.

Twenty-five of those patients were followed for a yearlong study also presented at the meeting. Some of those patients did better, but one ended up doing worse. “A drug can induce an increase in seizures,” says Dr. Maria Roberta Cilio, a pediatric neurologist at UCSF Benioff Children’s Hospital who led that study. This happened with one of her patients. “For one particular child, the more the dose of [cannabidiol] was increasing, that increase was paralleled with an increase in seizure frequency,” she says.

Some patients in Devinsky’s trial also did worse while on cannabidiol, but he thinks there’s no way to tell if it was because of the drug or something else. He says we won’t know until a full clinical trial has run its course. Without that, the perceived effects of the drug might be a placebo effect or it could be some other confounding factor that hasn’t been caught in the study. What’s more, a few hundred patients isn’t a lot of patients, and doctors still need to see what will happen when a patient is on cannabidiol for more than a few months.

Epilepsy can be one of the most difficult syndromes to treat. About a third of patients have an intractable form of epilepsy. It’s common for children and adults with treatment-resistant epilepsy to exhaust the list of anti-seizure medications to little or no effect.

Jaren Hansen is a 7-year-old boy with Lennox-Gastaut Syndrome, a form of treatment-resistant epilepsy. When he was 2, he started having seizures. His doctors diagnosed him with epilepsy and started him on one anti-seizure medication. Then they added another, and then another.

Jaren Hansen, here with his mother, Nicole Hansen, has had seizures since he was 2.

Jaren Hansen, here with his mother, Nicole Hansen, has had seizures since he was 2. Courtesy of Nicole Hansen hide caption

toggle caption Courtesy of Nicole Hansen

None of them seemed to be working. “He tail spun again and had a tonic-clonic seizure every day. At that point, he was on three seizure medications, and we weren’t seeing any control. Things were just tumbling downward,” says his mother, Nicole Hansen from Necedah, Wisc. “At one point, blood levels of Depakote [an anti-epileptic medication] were toxically high. We needed to try something else. We were scared for his long-term health based on just the side effects of the medicine.”

Hansen, who works as a cranberry grower in Wisconsin, started researching her son’s illness. She found an online chat group with other parents who were discussing medical cannabis, and decided to try one of the commercially available cannabidiol products. But it was difficult. States like Wisconsin do allow the shipment of cannabidiol supplements and oils that don’t contain tetrahydrocannabinol or THC, the psychoactive compound in marijuana, but most doctors won’t touch it. “They won’t even prescribe it because there are too many loopholes and too much work,” Hansen says.

Lack of physician input often leaves parents on their own, Hansen says. That presents more challenges. “You have to make sure the company can replicate the same product over and over. A small change in the ratio of THC to cannabidiol can cause the child’s seizures to increase or come back. You have to make sure there are no microbial issues like molds or funguses or pesticides.”

That people are treating themselves or their children with cannabis products is troubling to physicians. “It’s a very worrisome time. People go off and do their own thing, if things go wrong, you don’t know why. You want data, and you don’t have it, and all the families are just trying things,” says Dr. Brenda Porter, a pediatric neurologist at Stanford University School of Medicine who was not involved in the study.

Devinsky says parents either have to purchase the cannabidiol from an artisanal distributor of hemp products or compound the drug themselves. Either way, “the consistency from batch to batch is quite uncertain,” he says.

And people sometimes try different formulations from several companies in the hope one will work. “As a practitioner, I have had families move to Colorado, and many tried multiple different products,” Devinsky says. That makes it really difficult to tell what is or isn’t working. “As a doctor, I often don’t feel like I know which of many factors is contributing to a patient doing better or worse. We absolutely need rigorous, scientific data on this,” he says.

Even though the results presented at the American Epilepsy Society meeting look encouraging, researchers caution that there’s no promise cannabidiol is really going to work for many of these treatment resistant epilepsy syndromes. Until there is a full clinical trial done with a placebo-controlled element, Devinsky and others say it’s impossible to tell if cannabidiol is having a real effect on epilepsy. That takes time and puts parents in a difficult position, he says. “Parents are desperate and they feel the medical community has failed them, which is true in many cases.”

Hansen agrees with Devinsky; she feels that the clinical trials need to be finished as fast as possible. “There are parents out there doing whatever they can and experimenting with cannabis. We need the medical professionals so they can help make the proper recommendations,” she says. “But I can’t blame them for trying. When you are seeing your child dying, and knowing that you could do something to help them, how can you not do something as a parent?”

After Hansen put her son on cannabidiol he continued to have seizures, but the number of convulsive seizures went down. Then he caught a stomach flu, and things spiraled out of control. The tonic-clonic seizures came back, violently, and he nearly died. “They put him into am medically induced coma in hopes that it would reset his brain.” she says. “By God’s grace, truly, and by a miracle it did.”

Jaren is not on cannabidiol anymore. He’s on three different medications now, including a benzodiazepine and a barbiturate. “Both in the long-term can cause brain atrophy,” Hansen says. “At some point, we have to start weaning him off, and nothing else has worked. And he needs more than just cannabidiol.” She’s hopeful that cannabis research will bring the science to a point where doctors can begin looking into mixtures of cannabidiol and THC together.

Full on, randomized clinical trials testing cannabidiol for epilepsy are already underway, but it will still be some time until the results are out. Until then, Devinsky says, “Wait.”

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.


No Image

In Gaza, Kids With Cancer Have 'Virtually No Care.' One Group Hopes To Help

An interior view of the plans for the Gaza children's cancer treatment center.
3:51

Download

An interior view of the plans for the Gaza children’s cancer treatment center. Courtesy of CEP Consultants hide caption

toggle caption Courtesy of CEP Consultants

The ongoing conflict in the Gaza Strip has damaged hospitals, clinics and other medical facilities, leaving major gaps in health care.

Children with cancer, in particular, struggle to get the proper treatment they need. They often have to travel to Israel or much farther.

So one American nonprofit — called the Palestine Children’s Relief Fund — aims to change that. The PCRF is building a large new pediatric cancer center in Gaza.

“We found a significant gap in the services that are available in pediatric oncology and hematology. Our organization wants to address those, because children who are suffering from cancer have virtually no care at all in the Gaza Strip,” Steve Sosebee, co-founder and CEO of the group, tells NPR’s Lynn Neary.

“As you can imagine … the most basic chemotherapy, pain management, palliative care and so on being unavailable in Gaza is just a huge burden on the health care system, on the families and most importantly, on the patients.”


Interview Highlights

On the challenges children and their parents grapple with in Gaza

The problem facing children in Gaza far exceeds just the issue of cancer. Children in Gaza face food issues, face educational issues, face health care issues on a much larger scale than just cancer. And our organization addresses those issues.

On what kids with cancer in Gaza must do for treatment under current circumstances

Most of the kids are referred outside, if they’re able to get outside. There is no free access in and out of the Gaza Strip. You must have a permit from the Israeli army to leave the Gaza Strip.

Now, Israel does issue permits for humanitarian cases to leave and to go to Israeli hospitals for specialized oncological care. It’s an extremely long and bureaucratic process, and it’s also a very challenging one for the patients and for their families, because now, a new order just came down that children cannot travel with anyone under the age of 55. So it’s a big burden for the families. You can imagine that means the grandmother has to go.

On the challenges of building the center, given the political situation

Let me first give you a little bit of background. We built the first and only public pediatric cancer department in the West Bank, in Bethlehem, about two years ago. The problem is that those children in Gaza are unable to get out on a regular basis, therefore we need to build services for them in the Gaza Strip. About half of the population of Gaza are children. So it’s a very poor and impoverished land.

The challenges that we face are extreme. The political challenges are that getting equipment in is under the regulation and control of the Israeli military. The government in Gaza is run by Hamas, which the U.S. government deems as a terrorist organization, so there’s no contact with them. And getting things like cement in, getting drugs in is very challenging and extremely difficult.

On how far along in the construction process they are

We just finished the initial stages of the design being finalized, choosing a contractor, and we’ll start building before the end of this month. …

We hope, in the best-case scenario, that it will be done within one year. But unfortunately the circumstances now on the ground throughout the occupied territories is extremely volatile, and we do hope that the situation in Gaza will not deteriorate.

All we can do is try to provide services based on the needs of the people and not prevent the realities of working on the ground there to stop us from doing what our role and responsibility is, as a humanitarian organization — which is to look beyond politics, look beyond the religion and look strictly at the needs of the children there and try to serve those needs to the best of our ability.

This entry passed through the Full-Text RSS service – if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.